Main navigation
Unleash growth by optimising recombinant protein manufacture
Our QTL technology creates and customises premium recombinant proteins that are patent protected and designed to dominate your chosen market.
Solving big problems with support from the Bill & Melinda Gates Foundation
Our technology and expertise in genomics and strain breeding is making vaccines available to low and middle income countries using recombinant albumin. That’s just the start.
Therapeutics
Biosimilars
- Consistent high quality bioequivalence
- Higher titre and net yield
- Reduced manufacturing plant
- Overcoming manufacturing secrets
- Potential earlier market entry
Supply chain proteins
- Meet supply deficits
- Significantly lower costs
- Substantial scaling
- Technically challenging proteins
- Circumvent manufacturing secrets
Discovery biologics
- Commercially scalable
- Timely batches for testing
- Fast and dependable
- Regulatory friendly
- Attractive to licensors